Articles On Admedus (ASX:AHZ)

After another slow year for IPOs in 2023 – following an equally dismal 2022 – the ASX is set to see a flourish of new company activity in the last month of the year. Earlier this year, Morgan Stanley analysts predicted Australia’s IPO ma...

The Anteris Technologies Ltd (ASX: AVR) share price is shooting for the stars in early afternoon trade. This follows the structural heart company’s latest announcement that shows promising signs for its DurAVR THV system. Anteris, formerly...

ShareCafeHeart Innovator Anteris Takes on Medical Device Giants It’s been a rocky corporate journey for the ASX-listed Anteris Technologies over the years, but the heart device play holds rising hopes of cracking a $US11 billion ($14bn) glo...

The Anteris Technologies Ltd (ASX: AVR) share price is plunging today despite the company declaring “outstanding” results from one of its medical products. At the time of writing, shares in the medical technology company are trading at $11...

The Anteris Technologies Ltd (ASX: AVR) share price rose a jaw-dropping 23% today after an online investor presentation yesterday. The healthcare company opened the day at $5.85 and idled until an incredible rally just after midday shot th...

Anteris Technologies Ltd (ASX: AVR) shares will be on watch this morning following the release of the company’s preliminary results for the 2020 full year. At the closing bell yesterday, the Anteris share price finished the day down 3.8% a...

The Anteris Technologies Ltd (ASX: AVR) share price is edging higher today after releasing the results from its anti-clarification study. During early morning trade, shares in the structural heart company pushed as high as $3.84 but have s...

Anteris is a structural heart company with technology, ADAPT® and DurAVR™, that solves critical issues with marketed heart valves.

The aim of this study is to evaluate anti-calcification properties in the established subcutaneous rat model.

The aim of this study is to evaluate anti-calcification properties in the established subcutaneous rat model.

The company is focused on bringing DurAVR™ to market, building on the company’s cardiovascular patches using its ADAPT® tissue technology.

The company’s aortic valve, DurAVR™ was successfully implanted into the first patient at the University Hospitals, Leuven, in Belgium replicating results from animal and laboratory testing.

The first-in-human surgical aortic valve replacement (SAVR) trial is underway, with the first patient implanted with the proprietary ADAPT® single-piece 3D aortic valve.

Fifteen patients have been enrolled in the study and will be followed up for 6 months after receiving implantation of the ADAPT single-piece 3D aortic valve.

The company is conducting the first-in-hiuman surgical aortic valve study.

The company is focused on continuing to manufacture clinical solutions for healthcare professionals.

The first-in-human surgical aortic valve replacement study can now go ahead as planned starting this month.

Total revenue for the company was $17.1 million, which includes $10.2 million from sales of ADAPT® products and $6.9 million of Infusion products.

4C Medical’s implant utilises tissue processed by Admedus’ ADAPT Tissue Engineering Process for the functioning leaflet component of its valve.

The debut of Admedus' innovation suite at the world’s largest structural heart valve congress, PCR London Valves in the UK, generated a positive response amongst an audience of global key opinion leaders.

Admedus (ASX:AHZ) has announced the approval for first-in-human surgical aortic valve replacement (SAVR) trial of its proprietary ADAPT single-piece 3D aortic valve at the Leuven University Hospitals.

Admedus (AHZ) has received approval for the first in-human surgical aortic valve replacement trial for its ADAPT 3D aortic valve This trial comes after encouraging results from trials conducted on sheep Results from the human trial are ex...

The proposal follows Professor Meuris’ confidence in the prototype aortic valve after his recent investigation of the ADAPT® single-piece 3D aortic valve replacement in sheep.

Asia is rising as a healthcare spender, matching incomes and the long-feared elderly population boom. The region is a major part of a surge in health spending that is expected over the next few years, as rising lifestyle illnesses and ages...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition affecting more than 200 million people worldwide.

Shares have increased by around 50% this week after hitting 10.5 cents yesterday.

On this day in 1923, the Walt Disney Company was founded. A leader in the international entertainment industry, the company was created by brothers Walt and Roy as the Disney Brothers Cartoon Studio. Today, Disney is synonymous with cartoon...

Investors responded after Admedus was reinstated to official quotation, with shares surging 40% to an intra-day high of 8.4 cents.

Admedus (ASX: AHZ) shares have returned to trading after the structural heart company confirmed it would conduct a recapitalisation plan by selling its patch business to a US medical devices firm. In a statement to the market, Admedus annou...

CardioCel 3D® is used by surgeons to repair heart valves.

CardioCel 3D® is used by surgeons to repair heart valves.

In this week’s recap of substantial holders, James Baillieu has bought into Candy Club (ASX: CLB), WiseTech’s Michael Gregg bought into Oliver’s Real Foods (ASX: OLI) and Delphi bought a 14.6 per cent stake in Variscan Mines (ASX: VAR). Sub...

Invex Therapeutics Ltd (ASX: IXC) shares have now doubled from their July 3 initial public offer price of 40 cents to 85 cents this afternoon as investors turn bullish on a company backed by Fortescue Metals Group Limited (ASX: FMG) chairm...

In this week’s recap of substantial holder movements four substantial holders bought shares in Zenith Energy (ASX:ZEN), a Shanghai investor bought into Anson Resources (ASX:ASN) and Sirtex’s founder bought into Syrah Resources (ASX:SYR). Su...

Admedus (ASX:AHZ) has announced the publication of an independent study assessing the performance of CardioCel in the peer-reviewed journal, The Annals of Thoracic Surgery.

Earbuds maker Nuheara (ASX:NUH) surprised and dismayed the market this morning telling investors it received a takeover offer in April and is scrapping a new product unveiled in January last year. Nuheara did not identify the “large multina...

The study had positive outcomes, showing that the valve replacement devices had good durability.

Up until about four years ago obesity was an ‘it’ investment trend, as global funds spruiked the ‘sugar is the new tobacco’ theme and companies tested treatments specifically targeted at weight loss. Since then the world has not become any...

Up until about four years ago obesity was an ‘it’ investment trend, as global funds spruiked the ‘sugar is the new tobacco’ theme and companies tested treatments specifically targeted at weight loss. Since then the world has not become any...